When an Air India flight crashed into a medical campus, surviving doctors rushed to save lives
AHMEDABAD, India — Navin Chaudhary had just begun eating his meal when a loud bang startled him. He turned back to see a massive fire taking over the dining area where he and other trainee doctors had assembled for lunch.
The blaze approaching him, he rushed toward a window and jumped.
From the ground, looking upward, the sight of the Air India plane's tail cone hanging from the burning building propelled Chaudhary and fellow medical students into action.
'There was fire and many were injured,' said Chaudhary.
He said he felt lucky to survive but knew he had a task at hand. He rushed to the hospital's intensive care unit, where the injured, most of whom had burns, were wheeled in on stretchers.
'I felt that as a doctor I could save someone's life,' he said. 'I was safe. So I thought, whatever I can do, I should.'
At least 270 died when the Air India flight crashed into the campus of a medical college in Ahmedabad shortly after takeoff on Thursday. Only one passenger among the 242 aboard survived. At least 29 others on the ground, including five medical students inside the hostel, were also killed.
Many believe that the death toll would have been higher if it had not been for the intervention of the trainee doctors and students who emerged from the smouldering hostel and rushed to save their colleagues.
Akshay Zala, a senior medical student, said the crash felt 'like an earthquake.'
'I could hardly see anything as thick plumes of smoke and dust engulfed everything. I was barely able to breathe,' he said.
Zala rushed to safety, running through dust and smoke. He cleaned and bandaged a wound on his left leg then joined others at the medical college's trauma center to treat the injured.
On Monday, the crash site teemed with excavators and workers clearing the debris. Officials inspected the building in search of clues that could enable the investigators to figure out what led to the tragedy.
Barely a kilometer (less than a mile) away, trainee doctors who survived one of India's worst aviation disasters were still working to identify the victims through DNA testing.
Indian authorities have so far handed over the remains of 47 victims The bodies of 92 others have also been identified through DNA matching and will be transferred to relatives soon.
College dean Minakshi Parikh said that many of the doctors who pulled their colleagues out of the debris, later that day went back to their duties to save as many lives as they could. 'They did that and that spirit has continued till this moment,' Parikh said.
Images of the hostel's dining area shortly after the crash showed parts of the aircraft and pieces of luggage strewn on the floor. Dining plates still containing food lay on the few dusty tables that were left intact by the impact.
'So that is human nature, isn't it? When our own people are injured, our first response is to help them,' Parikh said. 'So the doctors who managed to escape ... the first thing that they did was they went back in and dug out their colleagues who were trapped inside.'
'They might not even have survived because the rescue teams take time coming,' she added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
VSA Signs Letter of Intent to Acquire HopeAI, Accelerating Expansion into AI in Life Science
BEIJING, June 17, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (Nasdaq: VSA) (the "Company" or "VSA") today announced that it has entered into a non-binding letter of intent ("LOI") to acquire HopeAI Inc. ("HopeAI"), a leading artificial intelligence company specializing in AI-powered clinical development. This strategic move is expected to significantly advance VSA's expansion into the AI biopharmaceutical sector and strengthen its presence in intelligent healthcare and technology innovation. Pursuant to the LOI, the Company agreed to acquire 100% of the equity interests of HopeAI in exchange for a certain amount of restricted Class A ordinary shares of VSA to be determined based on the valuation of HopeAI. As the transaction proceeds, the Company will publicly disclose required information either through press releases or SEC filings, as appropriate. Founded in 2023, HopeAI is an emerging enterprise dedicated to solving key challenges pharmaceutical companies face in clinical trials, including lengthy durations, large sample sizes, slow patient recruitment, and high costs. The company optimizes trial design and accelerates development timelines by integrating comprehensive and up-to-date clinical evidence with decades of statistical innovations. HopeAI's proprietary PURE Evidence, SynthIPD, and CARA Design platforms provide intelligent and efficient solutions across crucial trial stages such as protocol design, trial simulation, and patient cohort optimization. Its platform has successfully helped partner pharmaceutical companies reduce clinical timelines by up to 2.5 years, reduce Phase 3 trial sample sizes by up to 20%, save over 100 patient samples, and respond to FDA feedback within 24 hours—substantially improving drug development efficiency and regulatory communication speed. Henry Wang, CEO of VSA, stated, "HopeAI is highly aligned with our vision for technological innovation and industry development. This acquisition will create a powerful competitive advantage for VSA in the AI space and holds deep strategic significance." In 2024 alone, pharmaceutical companies spent over $200 billion on clinical development, with average clinical development taking 9 years. HopeAI's AI-driven platform is poised to dramatically shorten trial duration, reduce costs, and accelerate time-to-market for new drugs, helping to drive innovation across the life sciences sector. Will Ma, CEO of HopeAI commented, "the signing of this letter of intent marks a major milestone in HopeAI's journey. It represents a pivotal step toward accelerating our growth and expanding our market share in the AI pharmaceutical industry. Our mission is to bring hope to patients by accelerating the development of life-saving treatments through AI." Completion of the transaction contemplated by the LOI is subject to due diligence investigations by the relevant parties, the negotiation and execution of a definitive share purchase agreement, satisfaction of the conditions negotiated therein including the approval of the Company's Board of Directors and shareholders, satisfaction of Nasdaq listing requirements, and the satisfaction of other customary closing conditions. There can be no assurance that a definitive agreement will be entered into or that the proposed transaction will be consummated. Further, readers are cautioned that those portions of the LOI that describe the proposed transaction, including the consideration to be issued therein, are non-binding. About HopeAI Since its founding in 2023, HopeAI—under the leadership of Founder & CEO Will Ma—has assembled a world-class research team, including world-renowned experts in clinical trial design, a former AI researcher from NVIDIA, and the former biostatistics director from the US FDA. As a Mayo Clinic Platform_Accelerate company, HopeAI has access to their state-of-the-art real-world data platform to support clinical development. HopeAI has established commercial partnership with two of top 10 pharma companies, and several innovative biotech companies. HopeAI is also the first company of its kind to achieve commercial validation in the AI drug development space. About VSA VSA is an emerging technology services company , specializing in biomedical applications, research & development, and online education. We are dedicated to advancing AI-powered healthcare and biotech solutions that transform industries. Our mission is to empower individuals and organizations through intelligent systems, bridging innovation with real-world impact to create a smarter, more connected future. Forward-Looking Statements Certain statements made herein are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include timing of the proposed transaction; the business plans, objectives, expectations and intentions of the parties once the transaction is complete, and VSA's estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the occurrence of any event, change or other circumstances that could give rise to the terms of the LOI not hereafter being memorialized in a definitive agreement; the outcome of any legal proceedings that have been, or will be, instituted against VSA or other parties to the LOI following announcement of the LOI and transactions contemplated therein; the ability of VSA to meet NASDAQ listing standards following the transaction and in connection with the consummation thereof; the inability to complete the transactions contemplated by the LOI due to the failure to obtain approval of the stockholders of VSA or other closing conditions to; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the announcement of the LOI and consummation of the transaction described therein; costs related to the proposed acquisition; changes in applicable laws or regulations; the ability of the post-transaction company to meet its financial and strategic goals, due to, among other things, competition, the ability of the post-transaction company to grow and manage growth profitability, maintain relationships with customers and retain its key employees; the possibility that the post-transaction company may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by VSA. Additional information concerning these and other factors that may impact our expectations and projections can be found in our periodic filings with the SEC, including our Annual Report on Form 20-F for the fiscal year ended December 31, 2024. VSA's SEC filings are available publicly on the SEC's website at VSA disclaims any obligation to update the forward-looking statements, whether as a result of new information, future events or otherwise. Non-Solicitation This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of VSA or HopeAI., nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. View original content: SOURCE TCTM Kids IT Education Inc. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
GSK Licenses Shigella Vaccine to Bharat Biotech
GSK plc (NYSE:GSK) is . On June 12, the company announced licensing its Shigella vaccine candidate to Bharat Biotech. The licensing is part of the company's effort to get the vaccine to patients where the pathogen poses a significant threat of causing death from diarrhea. A closeup of a vial of the biotechnology company's vaccines. Shigella is responsible for the deaths of tens of thousands of children under five years in low and middle-income countries. GSK has developed altSonflex 1-2-3 to address the unmet need. Phase 1 and interim Phase 2 data of the candidate vaccine have already met the company's immunogenicity success criteria. Bharat Biotech will take charge of the continued development of altSonflex1-2-3, which encompasses Phase 3 clinical trials, regulatory progress, and large-scale production. GSK will support the initiative by helping design clinical trials, obtaining external financing, and aiding in access, delivery, and commercialization strategies. GSK plc (NYSE:GSK) is a global pharmaceutical company focused on the discovery, development, and manufacture of medicines and vaccines. Its products are distributed worldwide through a broad network of wholesalers, pharmacies, hospitals, and healthcare providers. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Stocks Analysts Are Upgrading Today and 13 Best AI Stocks to Buy Under $10. Disclosure: None.
Yahoo
5 hours ago
- Yahoo
Clover Initiates Phase I Clinical Trial for RSV + hMPV ± PIV3 Respiratory Combination Vaccine Candidates
-- Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- SHANGHAI, June 17, 2025 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world, today announced that enrollment of the first participants has been completed in a Phase I clinical trial evaluating SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3) respiratory combination vaccine candidates based on prefusion-stabilized F (PreF)-Trimer subunit vaccine antigens utilizing Clover's Trimer-Tag vaccine technology platform. "We are pleased to announce the Phase I clinical trial initiation of our potential first-in-class combination vaccine candidates SCB-1022 (RSV+hMPV) and SCB-1033 (RSV+hMPV+PIV3), further demonstrating the differentiated value of our validated Trimer-Tag platform," said Joshua Liang, Chief Executive Officer & Board Director of Clover. "While currently approved protein-based RSV vaccines are safe & effective, critical gaps persist globally, including the inability to prevent significant respiratory disease burden caused by other viruses related to RSV such as human metapneumovirus (hMPV) and parainfluenza virus type 3 (PIV3). Thus, we look forward to the clinical trial results for our respiratory combination vaccine candidates in order to maximize our impact on public health globally." In October 2024, Clover announced Phase I results in 70 older adults (60-85 years) for Clover's non-adjuvanted RSV PreF vaccine candidate (SCB-1019) compared head-to-head to GSK's AS01E-adjuvanted RSV vaccine (AREXVY), and results indicated a potential best-in-class combined immunogenicity & tolerability profile of SCB-1019. These results supported the further development and evaluation of SCB-1019 in combination with the PreF-Trimer antigens for hMPV and PIV3, which are also utilizing the Trimer-Tag platform. The ongoing Phase I trial for Clover's combination vaccine candidates is enrolling up to 192 older adults (60-85 years), and the participants will be randomized to receive either SCB-1022 (RSV+hMPV), SCB-1033 (RSV+hMPV+PIV3) or SCB-1019 (RSV) comparator. The study will assess safety, reactogenicity and immunogenicity. About Clover Clover Biopharmaceuticals is a global commercial-stage biotechnology company committed to unleashing the power of innovative vaccines to save lives and improve health around the world. With integrated research and development, manufacturing and commercial capabilities as well as strong partnerships with organizations globally, Clover has a diverse pipeline of candidates that have the potential to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable. Clover Forward-looking Statements This press release contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time. View original content: SOURCE Clover Biopharma Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data